for FAM81A (P < 0.0001), and 1.06 and 1.80 for PCSK6 (P < 0.0001), respectively. Univariate Cox proportional hazards regression analysis showed that gender (P [ 0.0082), urinary cytology (P [ 0.0300), and tumor grade (P [ 0.0151) had a significant effect on recurrence-free survival. In multivariate analyses, gender was an independent prognostic factor for recurrence-free survival (P [ 0.0356, risk ratio 2.95, 95% confidence interval 1.08-7.34). Univariate Cox proportional hazards regression analysis showed that FAM81A (P [ 0.0022), and PCSK6 (P [ 0.0147) copy number had a significant effect on progression-free survival. In multivariate analyses, FAM81A copy number was an independent prognostic factor for progression-free survival (P [ 0.0419, risk ratio 7.59, 95% confidence interval 1.07-153.42).
INTRODUCTION AND OBJECTIVES: Non-muscle invasive bladder cancer current scoring models cannot precisely predict the individual disease course and do not reflect the optimal treatment. Furthermore, in the era of precision medicine, it is unconceivable that risk stratification might disregard molecular features of cancer, and the imprecision of these risk tools based on combined pathological and clinical features highlight the requirement of molecular biomarkers able to personalize treatments. Circulating tumor cells (CTCs) are regarded as surrogates for early metastatic spread of disease. In addition, the molecular characterization of CTCs may represent a tool to investigate the basic mechanism of cancer biology since CTCs have the potential to give information regarding the intratumour heterogeneity and evolution.
METHODS: We conducted a prospective observational study in 102 patients with a pathologically confirmed high-risk T1G3 transitional cell tumor, treated at our Institution between 2010 and 2013 according to standard international guidelines (TURB followed by re-TURB and maintenance BCG). CTCs were isolated before the first TURB through CellSearch system. We had previously demonstrated that the presence of CTC is significantly associated with shorter TFR and TTP in a median follow up of 24 months. Updated outcome analysis and mature CSS and OS results are reported here in a median follow up of 63 months.
RESULTS: CTCs were found in 20/102 (20%) patients. Median CTCs number was 1 (range: 1-50). Patients that were still alive at the end of the study were followed for at least 61 months. The final analysis substantiated results obtained at 24 months of median follow-up showing a statistically significant p value for time to first recurrence, second recurrence and time to progression. The presence of at least 1 CTC was here found to be clearly associated also with shorter metastasis free survival, cancer-specific survival and overall survival. Multivariable analysis confirmed that CTCs, as compared to the standard predictive variables (multifocality, CIS, lymph vascular invasion) have the strongest negative prognostic impact for all the outcomes analyzed.
CONCLUSIONS: These results suggest that some patients with T1G3 NMIBC might have a clinically undetected systemic disease connoting CTCs as an useful tool to improve the currently used risk stratification algorithms. In conclusion, a closer follow-up, an early radical surgery or even a systemic treatment might be recommended in CTC positive NMIBC patients. METHODS: Prior expression profiling studies were reviewed to identify protein-coding gene panels associated with oncologic outcomes in bladder cancer. After excluding non-mappable genes, curated pathway analyses were used to enumerate direct and indirect interactions between mRNAs within the context of merged biological networks. Top ranking molecules, defined by the highest percentile of interactions, were evaluated for their prognostic potential in independent datasets. RESULTS: 825 shortlisted genes were used to construct two merged interactome networks. 8,776 direct and indirect molecular interactions were noted. The identified genes were percentile-ranked based on number of direct and indirect interactions with neighboring genes within curated pathways. 78 molecules contributed to the top 90 percentile of all interactions; merged analysis identified IFNG, TNF, TGFB1, IL2, TP53, ERBB2, and IL13 among the top 99-percentile of biomarkers. The top-ranked canonical pathways included intranuclear receptor signaling, activation and modulation of T lymphocytes, death receptor and interleukin signaling, and other pathways associated with molecular progression of cancer. The cellular functions associated with these networks included cell death, cell-cycle regulation, cell growth and proliferation, and cellular movement. The top biomarkers were then individually analyzed on three independent bladder cancer datasets (total, n[489 patients). ERBB2 overexpression was associated with higher rates of overall mortality in two datasets (p[0.002 and p[0.005), while IL13 overexpression was noted to be favorable for overall survival in another dataset (p[0.01). Merged canonical analysis also indicated that these may be druggable targets in bladder cancer.
CONCLUSIONS: We describe a metagenomic approach for identifying biomarkers that play putative crucial roles in modulating the molecular circuitry in bladder cancer. In addition to being consensus biomarkers generated from previously described and validated prognostic panels, these may also represent druggable targets in this disease.
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NEXT-GENERATION SEQUENCING REVEALS GENOMIC DIFFERENCES BETWEEN MALE AND FEMALE PATIENTS WITH UROTHELIAL CARCINOMA INTRODUCTION AND OBJECTIVES: While bladder cancer is more common in men, stage for stage women appear to have worse outcomes. Differences in genomic alterations may underlie this gender disparity, however few studies have examined this relationship.
